{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:17:12Z","timestamp":1769127432969,"version":"3.49.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Scientific Research Flanders","award":["grant number 3G037618"],"award-info":[{"award-number":["grant number 3G037618"]}]},{"name":"Scientific Research Flanders","award":["grant number 3G037618"],"award-info":[{"award-number":["grant number 3G037618"]}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Research suggests that respiratory and cardiovascular drugs can ameliorate the rate of lung function decline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the impact of respiratory and cardiovascular pharmacotherapy on lung function trajectories in the general population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Repeated spirometry was performed in the Rotterdam Study, a population-based cohort of adults aged \u2a7e45 years. Exposure to long-acting \u03b22-agonists (LABAs), long-acting muscarinic antagonists, inhaled corticosteroids (ICS), cardioselective \u03b2-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins was quantified from pharmacy records to account for therapy adherence. Propensity score matching and multinomial logistic regression were performed to model medication effects on lung function trajectories, which were previously identified on the basis of forced expiratory volume in 1 second and forced vital capacity patterns. Models were also stratified by genetic variation in each drug target.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 3,783 individuals, 2,974 (78.6%) were classified as normal lung function decliners, 432 (11.4%) as rapid decliners, and 377 (10.0%) as improvers. Exposure to LABA (odds ratio [OR], 1.09 [95% confidence interval (CI), 1.03\u20131.16] per 10% increase in exposure), ICS (OR, 1.08 [95% CI, 1.02\u20131.14]), and statins (OR, 1.04 [95% CI, 1.02\u20131.06]) significantly increased the odds of being an improver compared with a normal decliner. \u03b21-Blocker use was associated with higher odds of being a rapid decliner (OR, 1.04 [95% CI, 1.00\u20131.09]), which was driven by incident users. Pharmacogenetic analysis suggests that the effects of LABA, ICS, and \u03b21-blockers are dependent on genetic variation in their drug targets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study suggests that LABA, ICS, and statins may favorably modulate lung function trajectories in adults, whereas initiation of \u03b21-blockers was associated with rapid lung function decline.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202405-481oc","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T10:06:21Z","timestamp":1727085981000},"page":"54-63","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Respiratory and Cardiovascular Drug Exposure on Lung Function Trajectories"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4815-9067","authenticated-orcid":false,"given":"Xander","family":"Bertels","sequence":"first","affiliation":[{"name":"Department of Bioanalysis, Ghent University, Ghent, Belgium"},{"name":"Department of Epidemiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Vauterin","sequence":"additional","affiliation":[{"name":"Department of Bioanalysis, Ghent University, Ghent, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Riemann","sequence":"additional","affiliation":[{"name":"Department of Epidemiology"},{"name":"Department of Internal Medicine, and"},{"name":"Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frauke","family":"Van Vaerenbergh","sequence":"additional","affiliation":[{"name":"Department of Bioanalysis, Ghent University, Ghent, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristiaan","family":"Proesmans","sequence":"additional","affiliation":[{"name":"Department of Bioanalysis, Ghent University, Ghent, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 G.","family":"Uitterlinden","sequence":"additional","affiliation":[{"name":"Department of Epidemiology"},{"name":"Department of Internal Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Arfan","family":"Ikram","sequence":"additional","affiliation":[{"name":"Department of Epidemiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy G.","family":"Brusselle","sequence":"additional","affiliation":[{"name":"Department of Epidemiology"},{"name":"Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, the Netherlands; and"},{"name":"Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno H.","family":"Stricker","sequence":"additional","affiliation":[{"name":"Department of Epidemiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-4363","authenticated-orcid":false,"given":"Lies","family":"Lahousse","sequence":"additional","affiliation":[{"name":"Department of Bioanalysis, Ghent University, Ghent, Belgium"},{"name":"Department of Epidemiology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,1]]},"reference":[{"key":"2026012203072116400_bib1","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1056\/NEJMra1900475","article-title":"Update on the pathogenesis of chronic obstructive pulmonary disease","volume":"381","author":"Agusti","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012203072116400_bib2","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1136\/bmj.1.6077.1645","article-title":"The natural history of chronic airflow obstruction","volume":"1","author":"Fletcher","year":"1977","journal-title":"Br Med J"},{"key":"2026012203072116400_bib3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1164\/rccm.202301-0106PP","article-title":"Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary","volume":"207","author":"Agusti","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203072116400_bib4","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1164\/rccm.201209-1739PP","article-title":"\u03b22-agonist therapy in lung disease","volume":"187","author":"Cazzola","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203072116400_bib5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1164\/rccm.202005-1854OC","article-title":"Pharmacotherapy and lung function decline in patients with chronic obstructive pulmonary disease. A systematic review","volume":"203","author":"Celli","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203072116400_bib6","doi-asserted-by":"crossref","first-page":"1902119","DOI":"10.1183\/13993003.02119-2019","article-title":"Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD","volume":"55","author":"Mathioudakis","year":"2020","journal-title":"Eur Respir J"},{"key":"2026012203072116400_bib7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2213-2600(20)30105-3","article-title":"Prevalence and attributable health burden of chronic respiratory diseases, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"8","author":"GBD Chronic Respiratory Disease Collaborators","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026012203072116400_bib8","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1378\/chest.13-0799","article-title":"Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use","volume":"145","author":"Petersen","year":"2014","journal-title":"Chest"},{"key":"2026012203072116400_bib9","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.chest.2021.05.007","article-title":"Emphysema progression and lung function decline among angiotensin converting enzyme inhibitors and angiotensin-receptor blockade users in the COPDGene cohort","volume":"160","author":"Tejwani","year":"2021","journal-title":"Chest"},{"key":"2026012203072116400_bib10","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1378\/chest.07-0298","article-title":"The use of statins and lung function in current and former smokers","volume":"132","author":"Keddissi","year":"2007","journal-title":"Chest"},{"key":"2026012203072116400_bib11","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1164\/rccm.200705-656OC","article-title":"Statin use reduces decline in lung function: VA Normative Aging Study","volume":"176","author":"Alexeeff","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203072116400_bib12","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa1403086","article-title":"Simvastatin for the prevention of exacerbations in moderate-to-severe COPD","volume":"370","author":"Criner","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012203072116400_bib13","doi-asserted-by":"crossref","first-page":"00624-02020","DOI":"10.1183\/23120541.00624-2020","article-title":"Effect of beta-blockers on the risk of COPD exacerbations according to indication of use: the Rotterdam study","volume":"7","author":"Karimi","year":"2021","journal-title":"ERJ Open Res"},{"key":"2026012203072116400_bib14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.pupt.2012.10.008","article-title":"Statins, systemic inflammation and risk of death in COPD: the Rotterdam study","volume":"26","author":"Lahousse","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"key":"2026012203072116400_bib15","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3390\/jcm8111835","article-title":"\u03b22-Adrenergic receptor (ADRB2) gene polymorphisms and risk of COPD exacerbations: the Rotterdam study","volume":"8","author":"Karimi","year":"2019","journal-title":"J Clin Med"},{"key":"2026012203072116400_bib16","doi-asserted-by":"crossref","first-page":"1900521","DOI":"10.1183\/13993003.00521-2019","article-title":"The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD","volume":"54","author":"Obeidat","year":"2019","journal-title":"Eur Respir J"},{"key":"2026012203072116400_bib17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S2213-2600(18)30529-0","article-title":"Lung function trajectories in health and disease","volume":"7","author":"Agusti","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026012203072116400_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1411532","article-title":"Lung-function trajectories leading to chronic obstructive pulmonary disease","volume":"373","author":"Lange","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012203072116400_bib19","doi-asserted-by":"crossref","first-page":"00793-02023","DOI":"10.1183\/23120541.00793-2023","article-title":"Clinical relevance of lung function trajectory clusters in middle-aged and older adults","volume":"10","author":"Bertels","year":"2024","journal-title":"ERJ Open Res"},{"key":"2026012203072116400_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10654-023-01094-1","article-title":"The Rotterdam study. Design update and major findings between 2020 and 2024","volume":"39","author":"Ikram","year":"2024","journal-title":"Eur J Epidemiol"},{"key":"2026012203072116400_bib21","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.anai.2021.02.029","article-title":"Inhibitory effect of calcium channel blockers on the deterioration of lung function in adult-onset asthma","volume":"126","author":"Tsuzuki","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026012203072116400_bib22","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1093\/eurheartj\/ehaa793","article-title":"Association of beta-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis","volume":"41","author":"Yang","year":"2020","journal-title":"Eur Heart J"},{"key":"2026012203072116400_bib23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"2026012203072116400_bib24","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the Global Lung Function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"key":"2026012203072116400_bib25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/CIRCULATIONAHA.118.038814","article-title":"Use of genetic variants related to antihypertensive drugs to inform on efficacy and side effects","volume":"140","author":"Gill","year":"2019","journal-title":"Circulation"},{"key":"2026012203072116400_bib26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12944-023-01983-0","article-title":"Genetic insights into the association of statin and newer nonstatin drug target genes with human longevity: a Mendelian randomization analysis","volume":"22","author":"Chen","year":"2023","journal-title":"Lipids Health Dis"},{"key":"2026012203072116400_bib27","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/s41588-018-0205-x","article-title":"Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits","volume":"50","author":"Evangelou","year":"2018","journal-title":"Nat Genet"},{"key":"2026012203072116400_bib28","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ng.2797","article-title":"Discovery and refinement of loci associated with lipid levels","volume":"45","author":"Willer","year":"2013","journal-title":"Nat Genet"},{"key":"2026012203072116400_bib29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejim.2019.02.014","article-title":"Mortality associated with cardiovascular drugs in patients with chronic obstructive pulmonary disease and right-sided heart failure\u2014a Danish nationwide registry-based study","volume":"63","author":"Andersson","year":"2019","journal-title":"Eur J Intern Med"},{"key":"2026012203072116400_bib30","doi-asserted-by":"crossref","first-page":"230103","DOI":"10.1183\/16000617.0103-2023","article-title":"Methods to assess COPD medications adherence in healthcare databases: a systematic review","volume":"32","author":"Vauterin","year":"2023","journal-title":"Eur Respir Rev"},{"key":"2026012203072116400_bib31","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2022"},{"key":"2026012203072116400_bib32","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the Tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"Joss"},{"key":"2026012203072116400_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"key":"2026012203072116400_bib34","volume-title":"WeightIt: weighting for covariate balance in observational studies","author":"Greifer","year":"2024"},{"key":"2026012203072116400_bib35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13742-015-0047-8","article-title":"Second-generation PLINK: rising to the challenge of larger and richer datasets","volume":"4","author":"Chang","year":"2015","journal-title":"Gigascience"},{"key":"2026012203072116400_bib36","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa1908142","article-title":"Metoprolol for the prevention of acute exacerbations of COPD","volume":"381","author":"Dransfield","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012203072116400_bib37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/bcp.12181","article-title":"\u03b2-Adrenoceptor blockers and pulmonary function in the general population: the Rotterdam study","volume":"77","author":"Loth","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"2026012203072116400_bib38","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1164\/rccm.200712-1869OC","article-title":"Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study","volume":"178","author":"Celli","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203072116400_bib39","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1183\/09031936.02.00283202","article-title":"Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids","volume":"19","author":"Barnes","year":"2002","journal-title":"Eur Respir J"},{"key":"2026012203072116400_bib40","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1378\/chest.120.1.258","article-title":"Alternative mechanisms for long-acting \u03b22-adrenergic agonists in COPD","volume":"120","author":"Johnson","year":"2001","journal-title":"Chest"},{"key":"2026012203072116400_bib41","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1164\/rccm.200508-1321OC","article-title":"Antiinflammatory effects of salmeterol\/fluticasone propionate in chronic obstructive lung disease","volume":"173","author":"Barnes","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203072116400_bib42","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1513\/pats.200402-010MS","article-title":"Interactions between corticosteroids and beta2-agonists in asthma and chronic obstructive pulmonary disease","volume":"1","author":"Johnson","year":"2004","journal-title":"Proc Am Thorac Soc"},{"key":"2026012203072116400_bib43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1165\/ajrcmb.13.1.7598936","article-title":"Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells","volume":"13","author":"Green","year":"1995","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026012203072116400_bib44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1378\/chest.95.1.209","article-title":"Comparison of respiratory effects of two cardioselective beta-blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension","volume":"95","author":"van Zyl","year":"1989","journal-title":"Chest"},{"key":"2026012203072116400_bib45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2026012203072116400_bib46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S2213-2600(19)30276-0","article-title":"Lung function decline in former smokers and low-intensity current smokers: a secondary data analysis of the NHLBI Pooled Cohorts Study","volume":"8","author":"Oelsner","year":"2020","journal-title":"Lancet Respir Med"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/1\/54\/66007954\/annalsats_22_1_54.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/1\/54\/66007954\/annalsats_22_1_54.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:07:45Z","timestamp":1769069265000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/22\/1\/54\/8380598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]},"published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202405-481oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1,1]]},"assertion":[{"value":"2024-05-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}